Use of miRNAs in Growth Hormone Deficiency (GHD)
New Potential Biomarkers for Diagnosis of Growth Hormone (GH) Deficiency and Early Assessment of Response to GH Treatment for Appropriate Personalization of Therapy
University of Parma
400 participants
Apr 13, 2023
OBSERVATIONAL
Conditions
Summary
This study aims at improving knowledge about the diagnosis of growth hormone deficiency (GHD) and treatment with growth hormone (GH), with the goal of providing information on the presence of new biomarkers, such as miRNAs, for diagnostic and therapeutic purposes, with the goal of establishing a personalized GH treatment scheme, optimizing resources, reducing costs, and improving outcomes.
Eligibility
Inclusion Criteria7
- Children with short stature and suspicion of GHD
- Subjects with organic GH deficiency
- patients having confirmed GHD enrolled for aim 1
- patients with growth failure and born SGA (\>4 yr of age)
- patients with Noonan and Turner syndrome and growth failure
- patients with short stature homeobox-containing gene deficiency (SHOXD) and growth failure
- \- Isolated idiopathic prepubertal naive GHD subjects on long-acting versus daily GH therapy
Exclusion Criteria1
- Subjects with underlying genetic conditions and chronic diseases
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06455956